Step 3: Sanofi com­mits up to $100M to opt-in on Al­ny­lam’s PhI­II RNAi he­mo­phil­ia tri­al

Al­ny­lam is step­ping up to the start­ing line for a Phase III study of its he­mo­phil­ia drug fi­tusir­an with Sanofi on board as a part­ner …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.